Envestnet Asset Management Inc. Has $18.27 Million Stock Position in Smith & Nephew SNATS, Inc. $SNN

Envestnet Asset Management Inc. decreased its position in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 7.4% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 503,494 shares of the medical equipment provider’s stock after selling 40,167 shares during the period. Envestnet Asset Management Inc. owned about 0.12% of Smith & Nephew SNATS worth $18,272,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Hantz Financial Services Inc. boosted its holdings in shares of Smith & Nephew SNATS by 1.4% in the 3rd quarter. Hantz Financial Services Inc. now owns 75,397 shares of the medical equipment provider’s stock valued at $2,736,000 after buying an additional 1,017 shares during the last quarter. Pinnacle West Asset Management Inc. lifted its stake in Smith & Nephew SNATS by 9.6% in the third quarter. Pinnacle West Asset Management Inc. now owns 11,315 shares of the medical equipment provider’s stock valued at $411,000 after acquiring an additional 990 shares during the last quarter. Truist Financial Corp bought a new position in shares of Smith & Nephew SNATS in the 3rd quarter valued at about $270,000. Vanguard Personalized Indexing Management LLC increased its stake in shares of Smith & Nephew SNATS by 14.1% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 39,568 shares of the medical equipment provider’s stock worth $1,436,000 after purchasing an additional 4,880 shares during the last quarter. Finally, Lorne Steinberg Wealth Management Inc. raised its holdings in shares of Smith & Nephew SNATS by 0.7% in the 3rd quarter. Lorne Steinberg Wealth Management Inc. now owns 264,320 shares of the medical equipment provider’s stock valued at $9,592,000 after purchasing an additional 1,880 shares during the period. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Smith & Nephew SNATS Stock Performance

Shares of Smith & Nephew SNATS stock opened at $36.16 on Friday. Smith & Nephew SNATS, Inc. has a twelve month low of $23.91 and a twelve month high of $38.79. The company’s fifty day moving average is $33.48 and its 200 day moving average is $34.79. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on SNN shares. Canaccord Genuity Group decreased their price objective on shares of Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating on the stock in a report on Tuesday, November 11th. Kepler Capital Markets raised shares of Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday, November 17th. Weiss Ratings reissued a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Wednesday, January 21st. Royal Bank Of Canada downgraded shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research report on Monday, December 15th. Finally, Wall Street Zen raised Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 10th. One equities research analyst has rated the stock with a Strong Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, Smith & Nephew SNATS has a consensus rating of “Hold” and an average target price of $35.75.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.